Express Pharma
Home  »  Latest Updates  »  Slower revenue growth at 6-quarter low in Q3FY15: CRISIL Research

Slower revenue growth at 6-quarter low in Q3FY15: CRISIL Research

0 7

Pharmaceuticals forecast to report above average topline growth

CRISIL Research expects India Inc’s revenue growth to slip to a six-quarter low of seven per cent on a year-on-year (y-o-y) basis in the December 2014 quarter. This tepid show will be due to weak performance of investment-linked sectors, stable currency exchange rates (y-o-y) impacting topline growth of export-oriented sectors, and weak global commodity prices.

Revenue growth was around nine per cent in the preceding quarter and 13 per cent in the December 2013 quarter. On the profitability front though, CRISIL Research foresees a marginal uptick in EBITDA margins.

Sectors reporting revenue growth include IT service providers, aluminium among commodities and among domestic consumption-oriented sectors, automobiles, pharmaceuticals, FMCG and telecom are expected to show above average topline growth.

EP News BureauMumbai

Leave A Reply

Your email address will not be published.